Evidence map›Paper›PMID 39520708›Full record

ArticleThe veterinary quarterly2024

New preclinical biomarkers for prion diseases in the cerebrospinal fluid proteome revealed by mass spectrometry.

Sonia Pérez-Lázaro, Tomás Barrio, Susana B Bravo, Eloisa Sevilla, Alicia Otero, María Del Pilar Chantada-Vázquez, Inmaculada Martín-Burriel, Jesús R Requena, Juan J Badiola, Rosa Bolea

Abstract read
In one paragraph

Article in The veterinary quarterly, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sonia Pérez-LázaroCentre for Encephalopathies and Emerging Transmissible Diseases, Faculty of Veterinary Sciences, University of Zaragoza - Agri-Food Institute of Aragon (IA2), Zaragoza, Spain.
Tomás BarrioUMR Institut National de La Recherche Pour L'Agriculture, L'Alimentation Et L'Environment (INRAE), École Nationale Vétérinaire de Toulouse (ENVT) 1225 IHAP (Interactions Hôtes-Agents Pathogènes), Toulouse, France.
Susana B BravoProteomic Unit, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela (CHUS), Santiago de Compostela, Spain.
Eloisa SevillaCentre for Encephalopathies and Emerging Transmissible Diseases, Faculty of Veterinary Sciences, University of Zaragoza - Agri-Food Institute of Aragon (IA2), Zaragoza, Spain.
Alicia OteroCentre for Encephalopathies and Emerging Transmissible Diseases, Faculty of Veterinary Sciences, University of Zaragoza - Agri-Food Institute of Aragon (IA2), Zaragoza, Spain.
María Del Pilar Chantada-VázquezProteomic Unit, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela (CHUS), Santiago de Compostela, Spain.
Inmaculada Martín-BurrielLaboratory of Genetics and Biochemistry (LAGENBIO), Faculty of Veterinary Sciences, University of Zaragoza - Agri-Food Institute of Aragon (IA2), Zaragoza, Spain.
Jesús R RequenaCIMUS Biomedical Research Institute & Department of Medical Sciences, University of Santiago de Compostela-IDIS, Santiago de Compostela, Spain.
Juan J BadiolaCentre for Encephalopathies and Emerging Transmissible Diseases, Faculty of Veterinary Sciences, University of Zaragoza - Agri-Food Institute of Aragon (IA2), Zaragoza, Spain.
Rosa BoleaCentre for Encephalopathies and Emerging Transmissible Diseases, Faculty of Veterinary Sciences, University of Zaragoza - Agri-Food Institute of Aragon (IA2), Zaragoza, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current diagnostic methods for prion diseases only work in late stages of the disease when neurodegeneration is irreversible. Therefore, biomarkers that can detect the disease before the onset of clinical symptoms are necessary. High-throughput discovery proteomics is of great interest in the search for such molecules. Here we used mass spectrometry to analyse the cerebrospinal fluid proteome in an animal prion disease: preclinical and clinical sheep affected with natural scrapie, and healthy sheep. Interestingly, we found 46 proteins in the preclinical stage that were significantly altered (

Indexed as

BiomarkersProteomeAnimalsMass SpectrometryPrion DiseasesProteomicsScrapieSheepSheep DiseasesBiomarkersProteomebiomarkerscerebrospinal fluiddiagnosismass spectrometryneurodegenerative diseasespreclinicalPrionscrapie

Identifiers

PMID39520708
PMCPMC11552261

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.